IL-17:IL-17RA Assay Service
●
Target
IL-17:IL-17RA
●
Description
Screening and/or profiling compounds or biologics that inhibit IL-17 binding to IL-17RA in a biochemical assay.
●
Synonyms
Interleukin 17, Interleukin 17 receptor, CTLA8, IL17, activity assay kit
●
Example Data
*Example only, final data may vary.
Assay Details
●
Assay Format
Chemiluminescent
●
Reference Compounds and IC50
Anti-IL-17A Antibody, 5 nM
●
Assay Principle
The IL-17RA[Biotin]:IL-17A Inhibitor Screening Assay is designed for screening inhibitors of IL-17A:IL-17RA interaction. The key to this kit is the high sensitivity of detection of biotin-labeled IL-17RA by streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, IL-17A is coated on a 96-well plate. Next, IL-17RA is incubated with IL-17A on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which is then measured using a chemiluminescence reader.
Target Details
●
Protein Family
Immunotherapy
●
UniProt
IL-17RA: Q96F46; IL-17A: Q16552
●
Background
IL-17A is a pro-inflammatory cytokine produced by TH17 cells that plays a key role in inflammation, autoimmunity, and host defense. It has been shown to stimulate the production of pro-inflammatory cytokines, namely IL-6 and IL-8, by synoviocytes. Due to its role as a mediator of inflammation, the IL-17 pathway has become a popular target for treating diseases that have a strong inflammatory component such as psoriasis, arthritis, Crohn’s disease, and ankylosing spondylitis.
Delivery
●
Estimated Turnaround
Two to three weeks following delivery of compounds
●
Results
Extensive report with raw and analyzed data, graphs, and detailed protocols. Includes positive control for inhibition.
